BIOLIFE SOLUTIONS WKN: A1XCF2 ISIN: US09062W2044 Kürzel: BLFS Forum: Aktien Thema: Hauptdiskussion

BioLife Solutions Announces Third Quarter 2021 Financial Results https://www.prnewswire.com/news-releases/biolife-solutions-announces-third-quarter-2021-financial-results-301422609.html Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue Raises full-year 2021 revenue guidance to $115 to $119 million, reflecting strong demand for proprietary biopreservation media products Conference call begins at 4:30 p.m. Eastern time today

BioLife Solutions (BLFS) Misses Q3 EPS by 11c https://www.streetinsider.com/dr/news.php?id=19200736 BioLife Solutions (NASDAQ: BLFS) reported Q3 EPS of ($0.20), $0.11 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.61 million. GUIDANCE: BioLife Solutions sees FY2021 revenue of $115-119 million, versus the consensus of $114.4 million.

UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines https://www.prnewswire.com/news-releases/unicef-selects-ultra-low-temperature-ult-freezers-from-biolife-solutions-to-extend-thermal-stability-of-covid-19-vaccines-301446062.html Stirling Ultracold Freezers to be Used in Africa, the Middle East and South America

BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results https://www.prnewswire.com/news-releases/biolife-solutions-reports-unaudited-fourth-quarter-and-full-year-2021-financial-results-301491979.html Record quarterly revenue of $37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64% Record full year revenue of $119.2 million up 148% over 2020, with organic revenue growth of 37% and biopreservation media revenue growth of 39% Initial guidance for 2022 total revenue at $159.5 million to $171 million, reflecting overall growth of 34% to 44% over 2021 and organic growth of 28% to 39%

Form NT 10-K - filed by Biolife Solutions Inc https://newsfilter.io/a/a9590c1ff554a9affb16836334cf8917 ... BioLife Solutions, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”) within the prescribed time period without unreasonable effort or expense. The Company is in the process of completing the financial statements to be included therein. The Company’s management is also in the process of assessing the effectiveness of the Company’s internal control over financial reporting. Although the assessment is not yet complete, the Company expects to report material weaknesses in the Company’s internal control over financial reporting. The Company expects to file the 2021 Form 10-K as soon as possible, but no later than March 16, 2022, the fifteenth calendar day following the prescribed due date of the 2021 Form 10-K. ...

BioLife Solutions Leverages Expanded Bioproduction Tools and Services Portfolio in Multipoint Engagement with Leading CAR T-Cell Developer https://www.prnewswire.com/news-releases/biolife-solutions-leverages-expanded-bioproduction-tools-and-services-portfolio-in-multipoint-engagement-with-leading-car-t-cell-developer-301391410.html CryoStor® Freezer Media, evo® Smart Shipper and SciSafe® Storage Services All Utilized to Support Potential Q4 US Regulatory Approval and 2022 Commercial Launch

BioLife Solutions Joins S&P SmallCap 600 Index https://markets.businessinsider.com/news/stocks/biolife-solutions-joins-s-p-smallcap-600-index-1030758292 ...today announced that its common stock will be added to the S&P SmallCap 600 Index effective prior to the opening of trading on Monday, August 30, 2021.  ...

BioLife Solutions Announces Second Quarter 2021 Financial Results https://www.prnewswire.com/news-releases/biolife-solutions-announces-second-quarter-2021-financial-results-301354677.html Total revenue grew 215% over Q2 2020 and 85% over Q1 2021 Organic revenue up 49% over Q2 2020 driven by 45% media revenue growth Full year revenue guidance raised to $108 to $117 million, reflecting expected contribution from Sexton Biotechnologies ...

BioLife Solutions to acquire Sexton Biotechnologies https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=3107

BioLife Solutions EPS beats by $0.01, beats on revenue https://seekingalpha.com/news/3696228-biolife-solutions-eps-beats-0_01-beats-on-revenue BioLife Solutions (NASDAQ:BLFS): Q1 Non-GAAP EPS of $0.01 beats by $0.01; GAAP EPS of -$0.03 beats by $0.01. Revenue of $16.85M (+38.6% Y/Y) beats by $0.8M. Full year revenue guidance raised to $106 to $115 million  vs. $105.65M reflecting confidence in outlook

👍

Stirling Ultracold Announces Merger Agreement with BioLife Solutions to Further Support Life-Science Industry with Expertise in Ultra-Low Temperature Storage https://www.prnewswire.com/news-releases/stirling-ultracold-announces-merger-agreement-with-biolife-solutions-to-further-support-life-science-industry-with-expertise-in-ultra-low-temperature-storage-301252910.html Unique expertise with a combined portfolio offering elevates BioLife Solutions to be the provider of choice for cell and gene therapies, scientific research, upstream pharmaceutical manufacturing and biologic sample storage.

BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results https://investors.biolifesolutions.com/2021-03-22-BioLife-Solutions-Announces-Fourth-Quarter-and-Full-Year-2020-Financial-Results Q4 total revenue of $14.7 million increased 78%, full year total revenue of $48.1 million increased 76% Introduces guidance for 2021 total revenue of $101 million to $110 million, up 110% to 129% over 2020 Conference call begins at 4:30 p.m. Eastern time today   ....

BioLife Solutions: Leading Life Science Tools Play https://seekingalpha.com/article/4395991-biolife-solutions-leading-life-science-tools-play Summary BioLife Solutions is a leading company focused on the cell therapy market. The company has demonstrated strong growth and market adoption even through COVID. The company has a differentiated technology platform that will allow them to take share over time. Valuation is healthy but given the company's product leadership and addressable market size, I believe there is still significant room for the stock to appreciate. Based on my 40x revenue multiple, I believe there is 29% upside from levels today. ...

https://www.prnewswire.com/news-releases/biolife-solutions--casdin-capital-innovation-accelerator-announce-new-investments-in-cell--gene-therapy-bioproduction-tools-301182184.html BioLife Solutions & Casdin Capital Innovation Accelerator Announce New Investments in Cell & Gene Therapy Bioproduction Tools Follow-on investment in iVexSol; Viral Vector Manufacturing Platform New investment in PanTHERA CryoSolutions; Freeze Media Technology